<DOC>
	<DOCNO>NCT02257827</DOCNO>
	<brief_summary>There randomize control trial ( RCT ) compare Conformal Radiotherapy ( 3DCRT ) versus Intensity Modulated Radiotherapy ( IMRT ) term toxicity disease control . Data retrospective study show IMRT reduces risk severe late complication . More recently , result RTOG 0126 study also confirm benefit IMRT reduce acute toxicity prostate cancer treat conventional dose escalation . Therefore , investigate real clinical benefit IMRT 3DCRT use hypofractionated schedule prostate cancer , investigator develop RCT .</brief_summary>
	<brief_title>Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy Treat Prostate Cancer With Hypofractionated Schedule</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients diagnosis prostate cancer With age 1875 year classify low Intermediate highrisk group accord Gleason score T stage initial PSA ( iPSA ) . Low risk group include patient Gleason score &lt; 7 / stage T1T2a , iPSA &lt; 10 ng/mL . Intermediate risk include Gleason score &lt; 7 , Stage T1T2b , iPSA level 1020 ng/mL Highrisk patient Gleason score &gt; 7 , Stage &gt; T2b , iPSA &gt; 20 ng/mL . All patient classify high risk submit bone scan . Patients metastases Prior history prostatectomy Pelvic radiotherapy treatment Chemotherapy treatment exclude trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hypofractionated schedule</keyword>
	<keyword>Intensity Modulated Radiotherapy</keyword>
	<keyword>Conformal radiotherapy</keyword>
</DOC>